Skip to main content

textochbilcontainer

A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT

textochbilcontainer

OUR CLINICAL pipeline CONSISTS of late stage drug candidates with a combined peak sales potential estimated at USD 350–700

textochbilcontainer

Moberg pharma intends to submit a registration application in Europe in 2021.

textochbilcontainer

We support Barncancerfonden

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.

Stockvalue 2013-05-20 14:00
32,90 kr
+2,5 %

Subscribe

Get our latest press releases and reports

 

Calendar/presentations

Next calendar event: 2021-02-09 Year-end report for the financial year 2020

RIGHTS ISSUE 2020

Moberg Pharma conducts a fully guaranteed rights issue in 2020, read more here

SPIN-OFF AND SEPARATE LISTING OF BUPI Q1 2021

Moberg Pharma has announced its intention to distribute the operations of BupiZenge® (BUPI) to the shareholders of Moberg Pharma by distributing its shares in the subsidiary OncoZenge AB through a Lex ASEA distribution before listing the OncoZenge on Nasdaq First North Growth Market in Q1 2021. Read more at OncoZenges webpage